PatenSee Achieves FDA Breakthrough Device Status
PatenSee, an innovative clinical-stage medical device firm, recently celebrated a major milestone—receiving Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its groundbreaking non-contact vascular access (VA) management technology aimed at enhancing the hemodialysis experience for patients.
Transforming Hemodialysis Through Innovation
With this prestigious FDA designation, the focus is now on streamlining the regulatory pathways for PatenSee's advanced platform, which seeks to minimize the clinical burden on healthcare providers while significantly improving patient outcomes. The technology harnesses the power of artificial intelligence to ensure comprehensive and touch-free physiological monitoring, firmly aligned with KDOQI guidelines.
Overcoming Clinical Challenges in Dialysis
The vascular access site, where an artery and vein connect, serves as a crucial element for patients undergoing hemodialysis. However, consistent monitoring of this site, while essential, often proves to be both tedious and prone to inconsistency. Complications arising from vascular access are among the foremost causes of patient morbidity and often contribute to increased healthcare costs and lower quality of life.
A Comprehensive Solution for Early Detection
PatenSee's technology aims to enable healthcare professionals to detect vascular access complications significantly earlier than is possible with the current standard of care. By fostering a standardized and streamlined monitoring process, this system not only serves to improve patient outcomes but also seeks to alleviate financial pressures on both healthcare providers and insurers.
Progressing Towards Clinical Validation
Currently, PatenSee is in the midst of conducting a pivotal clinical trial in partnership with Henry Ford Health, which seeks to rigorously validate the effectiveness of its monitoring system. This collaboration marks a key step in bringing their innovative technology closer to mass adoption within clinical settings.
Recent Funding to Propel Development
In an exciting development, the company has recently completed a $2 million seed funding round, spearheaded by Michigan Rise. The round saw participation from notable investors including Spark Capital, the Biosciences Research and Commercialization Centre at Western Michigan University, Kalamazoo Forward Ventures, and Edge Medical Ventures. This financial backing is set to enhance the capabilities of PatenSee as it advances through crucial stages of product development.
About PatenSee
PatenSee is committed to revolutionizing vascular access monitoring for hemodialysis patients through its non-contact solution, which employs advanced imaging technologies, artificial intelligence, and machine learning. The aim is to alert healthcare providers about stenosis risks as early as possible, facilitating timely interventions that protect patient lifelines and enhance the overall quality of care.
Founded within the supportive framework of the MEDX Xelerator venture studio and backed by the Israeli innovation authority, PatenSee has established its presence in both Detroit, Michigan, and Or Yehuda, Israel. The company is poised for success as it continues to refine its groundbreaking monitoring system.
Currently, PatenSee's system is classified as investigational and awaits FDA approval.
Frequently Asked Questions
What is the FDA Breakthrough Device Designation?
The FDA Breakthrough Device Designation is an initiative aimed at expediting the development and review processes for medical devices that demonstrate the potential to provide more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions.
How does PatenSee’s technology improve patient outcomes?
PatenSee’s technology enhances patient outcomes by facilitating early detection of vascular access complications, allowing for timely interventions that can prevent serious issues associated with hemodialysis.
What is hemodialysis, and why is vascular access important?
Hemodialysis is a process that filters waste and excess fluids from the blood, using an external machine. Vascular access is vital because it is the site through which blood is drawn from the body for filtering and returned to the body, making it critical for effective treatment.
What does the clinical trial with Henry Ford Health involve?
The clinical trial with Henry Ford Health is focused on validating the performance of PatenSee’s vascular access monitoring system, assessing its effectiveness in a real-world hospital setting.
What are the future plans for PatenSee?
PatenSee aims to refine its monitoring technology, achieve FDA approval, and ultimately improve the management of vascular access for hemodialysis patients, providing significant benefits to both patients and healthcare providers.
